X0203 3 2010-10-21 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001034196 ADVENT INTERNATIONAL CORP/MA 75 STATE STREET, 29TH FLOOR BOSTON MA 02109 0 0 0 1 Member of Group > 10% Common Stock 4172 I See Footnote Series A Convertible Preferred Stock Common Stock 1263312 I See Footnote Series B Convertible Preferred Stock Common Stock 441376 I See Footnote Senior Subordinated Convertible Promissory Notes 7.60 2011-12-31 Common Stock 814092 I See Footnote Reflects a 1-for-2.4417 reverse stock split effected on October 19, 2010 in connection with the Issuer's initial public offering. These securities are indirectly beneficially owned in the following capacities; as Manager of Advent International LLC, which in turn is the General Partner of AHLS III GP, which in turn is the General Partner of Advent Healthcare & Life Sciences III Limited Partnership and Advent Healthcare & Life Science III A Limited Partnership. Advent International Corporation is also the General Partner of Advent Partners HLS III Limited Partnership. The Series A Convertible Preferred Stock (the "Series A Shares") and the Series B Convertible Preferred Stock (the "Series B Shares") are convertible, in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation, at any time after the issuance of such shares, at the holder's election. The Series A Shares and the Series B Shares, including all accrued and unpaid interest thereon, will convert automatically into Common Stock without payment of any additional consideration, upon the closing of the Issuer's initial public offering and do not have an expiration date. The Series A Shares will convert on a 1-for-0.38701117412 basis and the Series B Shares will convert on a 1-for-0.61027657931 basis. Reflects $5,609,135.84 aggregate principal amount of senior subordinated convertible promissory notes (the "Convertible Notes"), dated September 2, 2008, December 11, 2008, July 2, 2009, January 28, 2010, June 14, 2010, August 13, 2010, and October 1, 2010. The outstanding principal and accrued and unpaid interest on these Convertible Notes shall automatically be converted into shares of common stock upon the closing of the Issuer's initial public offering. The outstanding principal and accrued and unpaid interest on these Convertible Notes shall automatically be converted into shares of common stock upon the closing of the Issuer's initial public offering at $7.60 per share, 80% of the Issuer's initial public offering price per share. /s/ Jarlyth H. Gibson, Compliance Officer 2010-10-22